MX2023013545A - Metodo terapeutico para gato con enfermedad renal cronica. - Google Patents
Metodo terapeutico para gato con enfermedad renal cronica.Info
- Publication number
- MX2023013545A MX2023013545A MX2023013545A MX2023013545A MX2023013545A MX 2023013545 A MX2023013545 A MX 2023013545A MX 2023013545 A MX2023013545 A MX 2023013545A MX 2023013545 A MX2023013545 A MX 2023013545A MX 2023013545 A MX2023013545 A MX 2023013545A
- Authority
- MX
- Mexico
- Prior art keywords
- kidney disease
- chronic kidney
- feline
- stage
- treating
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Urology & Nephrology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Zoology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021100475 | 2021-06-16 | ||
| PCT/JP2022/023876 WO2022265031A1 (ja) | 2021-06-16 | 2022-06-15 | 慢性腎臓病のネコの治療方法 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023013545A true MX2023013545A (es) | 2023-11-29 |
Family
ID=84527566
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023013545A MX2023013545A (es) | 2021-06-16 | 2022-06-15 | Metodo terapeutico para gato con enfermedad renal cronica. |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US12097177B2 (https=) |
| EP (1) | EP4356908B1 (https=) |
| JP (1) | JP7318818B2 (https=) |
| KR (1) | KR20240021749A (https=) |
| CN (1) | CN117396197A (https=) |
| AU (1) | AU2022294552A1 (https=) |
| BR (1) | BR112023023965A2 (https=) |
| CA (1) | CA3217697A1 (https=) |
| ES (1) | ES3054744T3 (https=) |
| MX (1) | MX2023013545A (https=) |
| WO (1) | WO2022265031A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2025501556A (ja) * | 2021-12-27 | 2025-01-22 | ソシエテ・デ・プロデュイ・ネスレ・エス・アー | 慢性腎臓病を診断及び治療するための組成物及び方法 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS58124778A (ja) | 1982-01-20 | 1983-07-25 | Toray Ind Inc | ５，６，７−トリノル−４，８−インタ−ｍ−フエニレンＰＧＩ↓２誘導体 |
| JPH075582B2 (ja) | 1986-01-24 | 1995-01-25 | 東レ株式会社 | ２，５，６，７−テトラノル−４，８−インタ−ｍ−フエニレンＰＧＩ▲下２▼誘導体 |
| JPH0662599B2 (ja) | 1987-10-16 | 1994-08-17 | 東レ株式会社 | ２，５，６，７―テトラノル―４，８―インタ―ｍ―フェニレンＰＧＩ２誘導体ならびにその製造法および用途 |
| CA2012081C (en) | 1989-03-14 | 2000-08-29 | Shigeki Itou | 2,5,6,7-tetranor-4,8-inter-m-phenylene pgi 2 derivatives |
| WO1998041210A1 (en) | 1997-03-14 | 1998-09-24 | Toray Industries, Inc. | Sustained-release prostaglandin i derivative preparation |
| ES2272914T3 (es) | 2003-05-20 | 2007-05-01 | Ethypharm | Composicion farmaceutica oral de liberacion sostenida. |
| CN101217960B (zh) | 2005-07-08 | 2010-12-15 | 东丽株式会社 | 用于改善尿毒症的治疗药和处置方法 |
| JPWO2016031949A1 (ja) | 2014-08-28 | 2017-06-22 | 東レ株式会社 | 慢性腎不全の治療薬 |
| CA3164676A1 (en) | 2019-12-23 | 2021-07-01 | Toray Industries, Inc. | Drug for preventing dialysis shift or renal death |
-
2022
- 2022-06-15 CN CN202280038404.2A patent/CN117396197A/zh active Pending
- 2022-06-15 MX MX2023013545A patent/MX2023013545A/es unknown
- 2022-06-15 US US18/565,161 patent/US12097177B2/en active Active
- 2022-06-15 CA CA3217697A patent/CA3217697A1/en active Pending
- 2022-06-15 JP JP2022542656A patent/JP7318818B2/ja active Active
- 2022-06-15 AU AU2022294552A patent/AU2022294552A1/en active Pending
- 2022-06-15 WO PCT/JP2022/023876 patent/WO2022265031A1/ja not_active Ceased
- 2022-06-15 EP EP22825019.7A patent/EP4356908B1/en active Active
- 2022-06-15 KR KR1020237035492A patent/KR20240021749A/ko active Pending
- 2022-06-15 ES ES22825019T patent/ES3054744T3/es active Active
- 2022-06-15 BR BR112023023965A patent/BR112023023965A2/pt not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| EP4356908A4 (en) | 2024-10-23 |
| US12097177B2 (en) | 2024-09-24 |
| WO2022265031A1 (ja) | 2022-12-22 |
| EP4356908A1 (en) | 2024-04-24 |
| CA3217697A1 (en) | 2022-12-22 |
| JP7318818B2 (ja) | 2023-08-01 |
| AU2022294552A1 (en) | 2023-11-02 |
| CN117396197A (zh) | 2024-01-12 |
| JPWO2022265031A1 (https=) | 2022-12-22 |
| US20240207218A1 (en) | 2024-06-27 |
| BR112023023965A2 (pt) | 2024-01-30 |
| EP4356908C0 (en) | 2025-10-22 |
| ES3054744T3 (en) | 2026-02-05 |
| KR20240021749A (ko) | 2024-02-19 |
| EP4356908B1 (en) | 2025-10-22 |
| TW202317089A (zh) | 2023-05-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Bourgonje et al. | N-acetylcysteine and hydrogen sulfide in coronavirus disease 2019 | |
| MXPA05010185A (es) | Metodos para tratar o prevenir un estado inflamatorio o metabolico por inhibicion de jnk. | |
| MX2023013978A (es) | Composicion fungicida que contiene compuestos de oxadiazol. | |
| ZA202200519B (en) | Piperidinyl-methyl-purineamines as nsd2 inhibitors and anti-cancer agents | |
| UA84056C2 (ru) | Фунгицидная композиция и способ борьбы с фитопатогенными грибками | |
| MA34837B1 (fr) | Composés indoliques ou analogues de ceux-ci utiles dans le traitement de la dégénérescence maculaire liée à l'âge (dmla) | |
| MA42678B1 (fr) | Nouveaux analogues nucléosidiques substitués à cycle aromatique bicyclique 6-6 pour une utilisation en tant qu'inhibiteurs de prmt5 | |
| WO2008012635A3 (en) | Amine derivatives useful as anticancer agents | |
| MY140525A (en) | Pharmaceutical uses for alpha2delta ligands | |
| UA98315C2 (ru) | Инсектицидная композиция, способ обработки сельскохозяйственных культур и применение композиции | |
| FR14C0047I1 (https=) | ||
| MX2024013914A (es) | Moduladores del inflamasoma nlrp3 y productos y metodos relacionados | |
| MXPA05009303A (es) | Formas de dosificacion y procedimientos de tratamiento que usan inhibidores del vegfr. | |
| WO2022133046A3 (en) | Compounds and compositions for treating conditions associated with sting activity | |
| MA42301B1 (fr) | Sel cristallin de fumarate de (s)-[3,4-difluoro-2-(2-fluoro-4-iodophénylamino)phényl][3-hydroxy-3-(pipéridin-2-yl)azétidin-1-yl]-méthanone | |
| MX2025005223A (es) | Agonistas del estimulador de genes de interferon (sting) | |
| MX2023013545A (es) | Metodo terapeutico para gato con enfermedad renal cronica. | |
| MX2025010256A (es) | Derivados de hidroquinazolina para el tratamiento de una enfermedad o un trastorno | |
| MX2024012882A (es) | Compuestos de liberacion de gamma-hidroxibutirato y procesos para fabricar y usar los mismos | |
| WO2020236690A9 (en) | Natriuretic peptide receptor a agonists useful for the treatment of cardiometabolic diseases, kidney disease and diabetes | |
| WO2022133098A3 (en) | Compounds and compositions for treating conditions associated with sting activity | |
| MX2025012154A (es) | Compuestos de pirimidina disustituidos para la inhibición de cetohexocinasa | |
| MX2024001817A (es) | Compuestos y composiciones para tratar condiciones asociadas con actividad de sting. | |
| JPH08268885A (ja) | 過酸化脂質増量抑制剤 | |
| BRPI0408039A (pt) | composição fungicida e método para o controle preventivo ou curativo de fungos fitopatogênicos |